Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Cancer is a disease which frequently has a poor prognosis. Although multiple therapeutic
strategies have been developed for various cancers, including chemotherapy, radiotherapy …

Despite the development of targeted therapy, drug resistance remains a primary hindrance
to curative treatment of various cancers. Among several novel approaches to overcome drug …

Protein biogenesis, maturation and degradation are tightly regulated processes that are
governed by a complex network of signaling pathways. The endoplasmic reticulum (ER) is …

Despite the rapid advancement in the introduction of new drugs for cancer therapy, the
frequent emergence of drug resistance leads to disease progression or tumor recurrence …

Prostate cancer (PC) is the second most common cause of death amongst men in the USA.
Therapy of PC has been transformed in the past decade by introducing novel therapeutics …

New treatment options of acute myeloid leukemia (AML) are rapidly emerging. Pre-clinical
models such as ex vivo cultures are extensively used towards the development of novel …

Leukemia is a fatal hematopoietic disorder with a poor prognosis. Drug resistance is
inevitable after the long‑term use of chemotherapeutic agents. Liproxstatin‑1, commonly …

Abstract T-complex protein 1 (TCP1) is one of the subunits of chaperonin-containing T
complex (CCT), which is involved in protein folding, cell proliferation, apoptosis, cell cycle …

Acute myeloid leukemia (AML) is a common and catastrophic hematological neoplasm with
high mortality rates. Conventional therapies, including chemotherapy, hematopoietic stem …